Friday, May 16, 2008


Ranbaxy drug-discovery with Merck

Even as Ranbaxy Laboratories fights the Battle for Lipitor with Pfizer, it has tied up with another global pharma giant Merck for joint drug discovery.

Merck is also working with another Indian drugmaker Nicholas Piramal to jointly develop cancer treatments (Pharma Acquisitions). Ranbaxy continues its old partnership with another global pharma giant GlaxoSmithKline in drug development (Ranbaxy GSK to develop respiratory drug)

Pharmaceutical Business

Ranbaxy Laboratories and Merck & Co have signed a strategic product development agreement providing for a drug discovery and clinical development collaboration for new products, in the anti-infective field.

Ranbaxy and Merck will work together to develop clinically validated antibacterial and anti-fungal drug candidates. Ranbaxy will carry-out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates thereafter. The agreement provides that the collaboration will begin in 2008 with an initial term of five years and can be extended mutually thereafter by the parties.

Under the terms of the agreement, Ranbaxy will be paid an undisclosed upfront sum, with the potential to receive payments totaling more than $100 million associated with the achievement of various research, development and regulatory approval milestones for each target included in the collaboration. Ranbaxy is also eligible to receive significant royalties on worldwide net sales of any products commercialized under the agreement.

Malvinder Mohan Singh, CEO and managing director of Ranbaxy, said: "This collaboration with Merck positions Ranbaxy to extend its capability set and move up the value chain for drug discovery and development."

Links to this post:

Create a Link

<< Home

This page is powered by Blogger. Isn't yours?